Aurinia Pharmaceuticals Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
/ 
Frequently asked questions
To buy Aurinia Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Aurinia Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Aurinia Pharmaceuticals Inc. is AUPH:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Aurinia Pharmaceuticals Inc. has its primary listing on NASDAQ. You can trade Aurinia Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Aurinia Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Aurinia Pharmaceuticals Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Aurinia Pharmaceuticals Inc..